studies

urothelial cancer (UC) - bladder cancer (BC), durvalumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsDANUBE (D vs C - all population), 2020 0.99 [0.83; 1.18] DANUBE (D vs C - PDL1>25%), 2020 0.89 [0.71; 1.11] 0.95[0.83; 1.09]DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 202020%1,106moderatenot evaluable progression or deaths (PFS)detailed resultsDANUBE (D vs C - all population), 2020 0.77 [0.54; 1.09] DANUBE (D vs C - PDL1>25%), 2020 1.24 [0.74; 2.08] 0.94[0.59; 1.50]DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020256%1,106moderatenot evaluable DORdetailed resultsDANUBE (D vs C - all population), 2020 0.35 [0.20; 0.62] DANUBE (D vs C - PDL1>25%), 2020 0.27 [0.13; 0.57] 0.32[0.20; 0.50]DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 202020%416moderatenot evaluable objective responses (ORR)detailed resultsDANUBE (D vs C - all population), 2020 0.36 [0.26; 0.49] DANUBE (D vs C - PDL1>25%), 2020 0.41 [0.27; 0.62] 0.38[0.29; 0.49]DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 202020%1,106moderatenot evaluable AE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.37 [0.27; 0.52] 0.37[0.27; 0.52]DANUBE (D vs C - all population), 202010%658NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsDANUBE (D vs C - all population), 2020 0.66 [0.43; 1.03] 0.66[0.43; 1.03]DANUBE (D vs C - all population), 202010%658NAnot evaluable SAE (any grade)detailed resultsDANUBE (D vs C - all population), 2020 1.01 [0.74; 1.39] 1.01[0.74; 1.39]DANUBE (D vs C - all population), 202010%658NAnot evaluable STRAE (any grade)detailed resultsDANUBE (D vs C - all population), 2020 0.50 [0.31; 0.81] 0.50[0.31; 0.81]DANUBE (D vs C - all population), 202010%658NAnot evaluable TRAE (any grade)detailed resultsDANUBE (D vs C - all population), 2020 0.13 [0.09; 0.21] 0.13[0.09; 0.21]DANUBE (D vs C - all population), 202010%658NAnot evaluable TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.10 [0.07; 0.15] 0.10[0.07; 0.15]DANUBE (D vs C - all population), 202010%658NAnot evaluable TRAE leading to death (grade 5)detailed resultsDANUBE (D vs C - all population), 2020 1.82 [0.16; 20.16] 1.82[0.16; 20.16]DANUBE (D vs C - all population), 202010%658NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsDANUBE (D vs C - all population), 2020 0.46 [0.26; 0.79] 0.46[0.26; 0.79]DANUBE (D vs C - all population), 202010%658NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12] 3.64[0.16; 81.12]DANUBE (D vs C - all population), 202010%658NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55] 0.45[0.02; 13.55]DANUBE (D vs C - all population), 202010%658NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35] 1.82[0.06; 54.35]DANUBE (D vs C - all population), 202010%658NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.05 [0.02; 0.13] 0.05[0.02; 0.13]DANUBE (D vs C - all population), 202010%658NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Arthritis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.25 [0.05; 1.24] 0.25[0.05; 1.24]DANUBE (D vs C - all population), 202010%658NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55] 0.45[0.02; 13.55]DANUBE (D vs C - all population), 202010%658NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.68 [0.15; 3.05] 0.68[0.15; 3.05]DANUBE (D vs C - all population), 202010%658NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.36 [0.07; 1.86] 0.36[0.07; 1.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12] 3.64[0.16; 81.12]DANUBE (D vs C - all population), 202010%658NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.11 [0.01; 0.89] 0.11[0.01; 0.89]DANUBE (D vs C - all population), 202010%658NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.15 [0.01; 3.01] 0.15[0.01; 3.01]DANUBE (D vs C - all population), 202010%658NAnot evaluable Gastritis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35] 1.82[0.06; 54.35]DANUBE (D vs C - all population), 202010%658NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 5.48 [0.27; 109.88] 5.48[0.27; 109.88]DANUBE (D vs C - all population), 202010%658NAnot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55] 0.45[0.02; 13.55]DANUBE (D vs C - all population), 202010%658NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.13; 6.48] 0.91[0.13; 6.48]DANUBE (D vs C - all population), 202010%658NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 2.74 [0.28; 26.45] 2.74[0.28; 26.45]DANUBE (D vs C - all population), 202010%658NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 6.46 [0.79; 52.82] 6.46[0.79; 52.82]DANUBE (D vs C - all population), 202010%658NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.04 [0.00; 0.62] 0.04[0.00; 0.62]DANUBE (D vs C - all population), 202010%658NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12] 3.64[0.16; 81.12]DANUBE (D vs C - all population), 202010%658NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35] 1.82[0.06; 54.35]DANUBE (D vs C - all population), 202010%658NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.06 [0.00; 0.97] 0.06[0.00; 0.97]DANUBE (D vs C - all population), 202010%658NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12] 3.64[0.16; 81.12]DANUBE (D vs C - all population), 202010%658NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsOut of scaleDANUBE (D vs C - all population), 2020 0.01 [0.00; 0.09] 0.01[0.00; 0.09]DANUBE (D vs C - all population), 202010%658NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.11 [0.01; 2.13] 0.11[0.01; 2.13]DANUBE (D vs C - all population), 202010%658NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12] 3.64[0.16; 81.12]DANUBE (D vs C - all population), 202010%658NAnot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35] 1.82[0.06; 54.35]DANUBE (D vs C - all population), 202010%658NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.23 [0.01; 5.02] 0.23[0.01; 5.02]DANUBE (D vs C - all population), 202010%658NAnot evaluable Rash TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12] 3.64[0.16; 81.12]DANUBE (D vs C - all population), 202010%658NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.06; 14.56] 0.91[0.06; 14.56]DANUBE (D vs C - all population), 202010%658NAnot evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35] 1.82[0.06; 54.35]DANUBE (D vs C - all population), 202010%658NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.02 [0.00; 0.29] 0.02[0.00; 0.29]DANUBE (D vs C - all population), 202010%658NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86] 0.91[0.02; 45.86]DANUBE (D vs C - all population), 202010%658NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsDANUBE (D vs C - all population), 2020 0.09 [0.00; 1.64] 0.09[0.00; 1.64]DANUBE (D vs C - all population), 202010%658NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-02 09:37 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237 - treatments: 854,374,1073,953,672,1080,862

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons